Related Experiment Video
Updated: Apr 8, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Progress in Tissue Specimens Alternative for the Driver Genes Testing of Non-small Cell Lung Cancer]
1Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Abstract:
Target treatment based on driver genes in advanced non-small cell lung cancer is very important currently. Tumor tissues is the gold standard for driver genes testing. However, most of patients could not get the gene information for lack of enough tissues. To explore the tissue specimens alternatives is a hot spot in clinical work. This report reviews the tissue specimen alternatives of driver gene testing in non-small cell lung cancer.
Insights
Targeted therapies for advanced non-small cell lung cancer rely on driver gene testing. This review explores alternative tissue specimens for essential gene information when tumor tissue is insufficient.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Advanced non-small cell lung cancer (NSCLC) treatment increasingly relies on targeted therapies.
- Driver gene identification is crucial for personalized treatment strategies in NSCLC.
- Tumor tissue biopsy is the current gold standard for driver gene testing.
Purpose:
- To review and discuss alternative tissue specimens for driver gene testing in non-small cell lung cancer.
- To address the challenge of insufficient tumor tissue for comprehensive genetic profiling.
- To highlight emerging methods for obtaining essential gene information in NSCLC patients.
Summary:
- Driver gene testing is vital for targeted treatment in advanced non-small cell lung cancer.
- Insufficient tumor tissue often prevents comprehensive genetic analysis.
- This review examines alternative tissue sources for driver gene testing in NSCLC.
Impact:
- Facilitates broader application of targeted therapies in NSCLC.
- Improves patient access to essential genetic information.
- Supports clinical decision-making by providing viable alternatives to tumor tissue biopsy.
